Recently Listed Cancer Firm OnKure's Innovative Approach to Breast Cancer Treatment Sparks Analyst Enthusiasm

BenzingaOct 11 02:43

OnKure Started at Outperform by Oppenheimer, OKI-219 Potential Cited

Seeking AlphaOct 11 01:32

This Builders FirstSource Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday

BenzingaOct 10 21:00

OnKure Therapeutics Initiated at Outperform by Oppenheimer

Dow JonesOct 10 20:17 · Ratings

OnKure Therapeutics Analyst Ratings

BenzingaOct 10 20:04 · Ratings

Oppenheimer Initiates OnKure Therapeutics(OKUR.US) With Buy Rating, Announces Target Price $35

Futu NewsOct 10 18:31 · Ratings